HIV / AIDS in the News

Zimbabweans Fleeing Xenophobia In South Africa Battle To Get HIV Medicine Back Home - healthpolicy-watch.news

 

Northern Light EMMC ramps up HIV prevention efforts amid case increase - newscentermaine.com

 

Hypertension Identified in Nearly Half of HAART Patients - EMJ

 

Northwestern University: Tumor-like tissue environments could hold clues to curing HIV - European AIDS Treatment Group

 

Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV - HealthDay

 

Gilead’s HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability - Fierce Pharma

 

GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised - Zacks Investment Research

 

UC Davis School of Medicine: Probiotic-derived bioactive metabolite reverses gut dysfunction and boosts HIV treatment response - European AIDS Treatment Group

 

For the first time, Gilead's HIV prevention franchise crosses $1B in quarterly sales - FirstWord Pharma

 

Florida pastor accused of having sex with teen, not disclosing HIV status - WDHN

 

Florida pastor accused of having sex with teen, not disclosing HIV status - Fox 59

 

Winter Haven pastor accused of sexual abuse did not disclose HIV status to teen, sheriff says - WFTV

 

Gilead lifts sales outlook on strong Q2 HIV growth despite acquisition-related loss - The Pharma Letter

 

Russia Says Its HIV Rates Are Falling. Experts Aren’t So Sure. - The Moscow Times

 

The Bull Case For Gilead Sciences (GILD) Could Change Following Deeper 2026 Losses Amid HIV, Oncology Growth - Yahoo Finance

 

Tumor-like tissue environments could hold clues to curing HIV - Medical Xpress

 

Canadian doctors form consortium to prevent potential ‘resurgence of the HIV epidemic’ - CBC

 

HIV's hidden history: New study reveals much deeper roots stretching back millions of years - Science X

 

Racial, Age Inequities Evident in Lenacapavir PrEP Uptake - Medscape

 

New monthly HIV prevention pill, in late-stage trials, could provide a giant step forward in stopping new HIV infections - UNAIDS

 

Once-weekly HIV pill as effective as daily dose, research shows - The Conversation

 

Curing HIV — How Far Have We Come? - amfAR | The Foundation for AIDS Research

 

Gilead's Steady Long-Term Growth Prospects in HIV and Expansion in Oncology Support a Wide Moat - Morningstar

 

No liability for scientific due diligence: California Supreme Court rejects bizarre lawsuit faulting Gilead for fully evaluating HIV drug before release - Genetic Literacy Project

 

Opinion: CT should not restrict HIV medication access - CT Mirror

 

Florida 'dope-smoking' pastor accused of sexually abusing teen, exposing him to HIV - WCIV

 

Polk Sheriff Judd: Church pastor with HIV arrested for sexually battering 14-year-old boy - wtsp.com

 

Gilead second-quarter sales rise 8%, beating Wall Street estimates - WTVB

 

Gilead’s Yeztugo beats forecasts as HIV PrEP franchise exceeds $1B - Endpoints News

 

Gilead second-quarter sales rise 8%, beating Wall Street estimates - WKZO